Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

The Top 5 Biosimilars Articles for the Week of June 16

June 20, 2025

FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar

January 31st 2025

By Skylar Jeremias

Article

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be approved for US patients.

The Top 5 Biosimilar Articles for the Week of January 27

January 31st 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 27, 2025.

Real-World UK, Ireland Study Confirms Long-Term Efficacy of SB5 in Psoriasis

January 30th 2025

By Skylar Jeremias

Article

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.

FDA Reviews Golimumab Biosimilar, Samsung Biologics Hits Record Sales, Japan Approves Stelara Biosimilar

January 30th 2025

By Cameron Santoro

Article

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese regulatory agency approved a Stelara biosimilar.

Integrating Biosimilars Into Retina and Neurology Practices Requires Careful Planning

January 29th 2025

By Derek Burns, PharmD, MBA, BCPS, BCSCP

Article

Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.

Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH

January 28th 2025

By Skylar Jeremias

Article

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to a Russian study that expanded on a previous phase 3 study.

Switching From Ustekinumab to Biosimilar SB17 Maintains Efficacy, Safety in Patients With Psoriasis

January 27th 2025

By Cameron Santoro

Article

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term comparable efficacy and safety up to week 52.

Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets

January 26th 2025

By Skylar Jeremias

Article

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory announcements regarding new biosimilar products in Europe and Canada.

No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar

January 25th 2025

By Deana Ferreri, PhD

Article

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant differences in lab markers or disease activity between those on Remicade and those switched to biosimilar CT-P13 (Inflectra).

The Top 5 Biosimilar Articles for the Week of January 20

January 24th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 20, 2025.